🟢 Teva Pharma is trading 4.2% up in pre-market after Phase 2a trial met its primary endpoint

Teva Pharma is trading 4.21% up now at $37.71 after announcing positive topline Phase 2a results for TEV '408 in celiac disease.

• Announced September 2, 2026; the trial showed statistically significant prevention of gluten-induced intestinal damage versus placebo.
• The treatment was well-tolerated, with no safety signals reported.
• An investor call is scheduled for 8:00 a.m. ET; the clinical update is the clearest explanation for the pre-market advance.